Abacavir News and Research

RSS
Abacavir sulfate, also known as Ziagen or ABC, is a type of medicine called a nucleoside reverse transcriptase inhibitor (NRTI). NRTIs block reverse transcriptase, a protein that HIV needs to make more copies of itself.
Injectable ART may have same effectiveness as standard oral treatments

Injectable ART may have same effectiveness as standard oral treatments

New computer models could help researchers to better predict side-effects of drugs

New computer models could help researchers to better predict side-effects of drugs

Tentative FDA approval of lopinavir/ritonavir oral pellet formulation closes treatment gap for children with HIV

Tentative FDA approval of lopinavir/ritonavir oral pellet formulation closes treatment gap for children with HIV

Haag-Streit Surgical receives FDA 510(k) clearance for intraoperative-OCT camera

Haag-Streit Surgical receives FDA 510(k) clearance for intraoperative-OCT camera

Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

FDA approves ViiV Healthcare's Triumeq tablets for treatment of HIV-1 infection

FDA approves ViiV Healthcare's Triumeq tablets for treatment of HIV-1 infection

Dolutegravir drug offers added benefit in HIV patients

Dolutegravir drug offers added benefit in HIV patients

Merck announces new data from ongoing C-WORTHY Study in HIV/HCV co-infected patients

Merck announces new data from ongoing C-WORTHY Study in HIV/HCV co-infected patients

European Commission approves ViiV Healthcare's Tivicay for treatment of HIV infected adults

European Commission approves ViiV Healthcare's Tivicay for treatment of HIV infected adults

More AIDS-defining illnesses and severe side effects occur with appropriate comparator therapy

More AIDS-defining illnesses and severe side effects occur with appropriate comparator therapy

WHO's new HIV treatment guidelines call for immediate ART for HIV-infected children

WHO's new HIV treatment guidelines call for immediate ART for HIV-infected children

GlaxoSmithKline's HIV/AIDS business joins Medicines Patent Pool

GlaxoSmithKline's HIV/AIDS business joins Medicines Patent Pool

Janssen announces U.S. prescribing information update for EDURANT tablets

Janssen announces U.S. prescribing information update for EDURANT tablets

Mylan licenses rights to produce and market generic versions of Gilead HIV/AIDS therapies

Mylan licenses rights to produce and market generic versions of Gilead HIV/AIDS therapies

FDA approves 152 antiretroviral drugs in association with PEPFAR to treat HIV/AIDS

FDA approves 152 antiretroviral drugs in association with PEPFAR to treat HIV/AIDS

All adult patients with HIV should be offered ART: International Antiviral Society-USA panel

All adult patients with HIV should be offered ART: International Antiviral Society-USA panel

Cipla, DNDi to develop ARV combination therapy for children with HIV/AIDS

Cipla, DNDi to develop ARV combination therapy for children with HIV/AIDS

Dolutegravir-based regimen demonstrates superiority over Atripla in treatment-naive adults with HIV-1

Dolutegravir-based regimen demonstrates superiority over Atripla in treatment-naive adults with HIV-1

Researchers identify mechanism key in drug allergy

Researchers identify mechanism key in drug allergy

Severe hypersensitivity reactions to anti-HIV drug occur through autoimmune mechanism

Severe hypersensitivity reactions to anti-HIV drug occur through autoimmune mechanism